Tisolagiline

Tisolagiline (INNTooltip International Nonproprietary Name; developmental code names KDS-2010, SeReMABI) is a potent, highly selective, and reversible monoamine oxidase B (MAO-B) inhibitor which is under development for the treatment of Alzheimer's disease and obesity.^[1][2][3][4] It is taken by mouth.^[1] Tisolagiline is being developed by NEUROBiOGEN and Scilex Bio.^[1][2] As of December 2024, it is in phase 2 clinical trials for Alzheimer's disease and obesity.^[1][2]

Other namesKDS-2010; KDS2010; SeReMABI

Drug classReversible monoamine oxidase B (MAO-B) inhibitor

CAS Number

• 1894207-44-3

PubChem CID

• 132023446

Quick facts Clinical data, Other names ...

Tisolagiline

Clinical data
Other names	KDS-2010; KDS2010; SeReMABI
Drug class	Reversible monoamine oxidase B (MAO-B) inhibitor
Identifiers
IUPAC name (2S)-2-[[4-[4-(trifluoromethyl)phenyl]phenyl]methylamino]propanamide
CAS Number	1894207-44-3
PubChem CID	132023446
ChemSpider	128942408
UNII	PCH79KLX33
ChEMBL	ChEMBL5314546
Chemical and physical data
Formula	C17H17F3N2O
Molar mass	322.331 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H](C(=O)N)NCC1=CC=C(C=C1)C2=CC=C(C=C2)C(F)(F)F
InChI InChI=1S/C17H17F3N2O/c1-11(16(21)23)22-10-12-2-4-13(5-3-12)14-6-8-15(9-7-14)17(18,19)20/h2-9,11,22H,10H2,1H3,(H2,21,23)/t11-/m0/s1 Key:XCUXYNYVUMLDKH-NSHDSACASA-N

Close

In 2025, research suggested that KDS-2010 could also be used in recovery of spinal cord injuries. In these injuries, there is an excess of glia cells which protect the site but inhibit neural repair. Use of the MAO-B inhibitor in animal models resulted in improved neurological and locomotor abilities.^[5][6]